BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» HY-209: a GPCR19 agonist inhibiting NLRP3 inflammasome activation as a potential therapeutic for atopic dermatitis
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Dermatologic
HY-209: a GPCR19 agonist inhibiting NLRP3 inflammasome activation as a potential therapeutic for atopic dermatitis
Sep. 13, 2022
No Comments
Researchers from Shaperon Inc. presented positive preclinical data for their clinical-stage candidate, sodium taurodeoxycholate (HY-209), demonstrating its therapeutic potential for atopic dermatitis.
BioWorld Science
Conferences
Targeted therapy
Dermatologic